Samuel N Marcus, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · El Camino Health Medical Network LLC
Looking this up.
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Marcus’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A50154 · Current
Licensed to practise in California · since 1991 · expires 2027-05-31 · University of Liverpool Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Mountain View Endoscopy Center, LPAmbulatory Surgery Center · Mountain View, CAOwner · accredited by JCInitial Accreditation1 inspection, 1 with deficiencies · last 2013-06-03: Requirements Met
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$94,597
Medicare paid this office $94,597 for 328 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 107 | $24,833 | $162 |
| Return visit (30+ min) | 154 | $24,593 | $112 |
| Biopsy of large bowel using a flexible endoscope | 53 | $6,846 | $129 |
| Short return visit (20+ min) | 71 | $6,120 | $76 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $5,900 | $97 |
See all 11 services
| Long return visit (40+ min) | 107 | $24,833 | $162 |
| Return visit (30+ min) | 154 | $24,593 | $112 |
| Biopsy of large bowel using a flexible endoscope | 53 | $6,846 | $129 |
| Short return visit (20+ min) | 71 | $6,120 | $76 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $5,900 | $97 |
| New patient visit (60+ min) | 25 | $5,148 | $206 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $4,969 | $216 |
| Diagnostic exam of large bowel using a flexible endoscope | 32 | $4,750 | $144 |
| New patient visit (45+ min) | 32 | $4,466 | $140 |
| New patient visit (30+ min) | 14 | $1,375 | $98 |
| Short return visit | 11 | $347 | $32 |
Procedures Medicare counted
| Colonoscopy | 30 | More than 54% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 18 | More than 49% of doctors who do this |
Who their Medicare patients are
328 Original Medicare patients in 2024. Average age 76 · Women 56% · Health risk score 1.02. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 73% · Coronary heart disease 29% · Diabetes 26% · Cancer 20% · Atrial fibrillation 17% · Chronic kidney disease 15% · Depression 13% · COPD 10% · Heart failure 9% · Stroke 5% · Dementia 3%.
The office billed $577,119, Medicare allowed $125,909 and paid $94,597; for 740 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 328 | 740 | 76 | 1.02 | $577,119 | $94,597 |
| 2023 | 289 | 687 | 75 | 0.90 | $494,941 | $83,836 |
| 2022 | 348 | 844 | 75 | 0.94 | $529,202 | $108,712 |
| 2021 | 356 | 868 | 76 | 0.99 | $559,757 | $119,559 |
| 2020 | 332 | 828 | 75 | 1.03 | $382,209 | $89,092 |
| 2019 | 377 | 906 | 75 | 1.09 | $464,254 | $104,689 |
| 2018 | 373 | 912 | 74 | 1.02 | $438,671 | $100,855 |
| 2017 | 305 | 588 | 74 | 1.04 | $473,995 | $69,345 |
| 2016 | 292 | 570 | 75 | 1.08 | $450,106 | $68,685 |
| 2015 | 323 | 618 | 75 | 1.02 | $496,839 | $79,862 |
| 2014 | 351 | 699 | 75 | 1.11 | $563,192 | $94,743 |
| 2013 | 359 | 697 | 74 | 1.00 | $593,097 | $97,572 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 137 | $22,201 | $109 |
| Long return visit (40+ min) | 60 | $13,055 | $155 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 36 | $7,934 | $220 |
| Biopsy of large bowel using a flexible endoscope | 58 | $7,064 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | $6,937 | $101 |
| Short return visit (20+ min) | 72 | $6,069 | $67 |
| Diagnostic exam of large bowel using a flexible endoscope | 30 | $4,375 | $146 |
| New patient visit (45+ min) | 18 | $2,512 | $140 |
| New patient visit (30+ min) | 22 | $2,000 | $91 |
2022: 14 services
| Return visit (30+ min) | 157 | $28,164 | $118 |
| Long return visit (40+ min) | 73 | $18,078 | $171 |
| Biopsy of large bowel using a flexible endoscope | 81 | $10,559 | $130 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 40 | $8,389 | $205 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 78 | $7,765 | $98 |
| Short return visit (20+ min) | 63 | $6,051 | $82 |
| New patient visit (45+ min) | 38 | $5,175 | $136 |
| Diagnostic exam of large bowel using a flexible endoscope | 27 | $4,305 | $159 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 20 | $4,225 | $211 |
| New patient visit (30+ min) | 34 | $2,966 | $87 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,736 | $210 |
| New patient visit (60+ min) | 12 | $2,072 | $173 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,576 | $99 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 11 | $546 | $50 |
2021: 12 services
| Long return visit (40+ min) | 105 | $22,430 | $156 |
| Return visit (30+ min) | 134 | $21,876 | $115 |
| Biopsy of large bowel using a flexible endoscope | 95 | $15,265 | $159 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 80 | $8,748 | $99 |
| New patient visit (45+ min) | 49 | $7,634 | $156 |
| Short return visit (20+ min) | 66 | $6,842 | $83 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 26 | $5,474 | $211 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $4,545 | $162 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $3,964 | $124 |
| New patient visit (60+ min) | 15 | $3,207 | $214 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,595 | $216 |
| New patient visit (30+ min) | 26 | $2,569 | $99 |
2020: 12 services
| Return visit (30+ min) | 150 | $20,811 | $93 |
| Short return visit (20+ min) | 128 | $10,987 | $67 |
| Biopsy of large bowel using a flexible endoscope | 78 | $10,691 | $137 |
| Long return visit (40+ min) | 56 | $9,262 | $125 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 65 | $7,678 | $110 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | $6,562 | $212 |
| New patient visit (45+ min) | 37 | $4,865 | $131 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $3,345 | $167 |
| New patient visit (30+ min) | 37 | $3,321 | $90 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 14 | $3,058 | $218 |
| New patient visit (60+ min) | 12 | $1,962 | $163 |
| Short return visit | 14 | $599 | $37 |
2019: 12 services
| Return visit (30+ min) | 175 | $22,035 | $95 |
| Long return visit (40+ min) | 66 | $11,062 | $130 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 53 | $10,656 | $201 |
| New patient visit (45+ min) | 73 | $10,305 | $141 |
| Biopsy of large bowel using a flexible endoscope | 89 | $10,087 | $113 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 101 | $9,360 | $90 |
| Short return visit (20+ min) | 94 | $6,455 | $64 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 27 | $5,715 | $212 |
| New patient visit (30+ min) | 36 | $3,006 | $84 |
| New patient visit (60+ min) | 15 | $2,865 | $191 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $2,753 | $162 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,542 | $212 |
2018: 14 services
| Return visit (30+ min) | 151 | $19,019 | $90 |
| Long return visit (40+ min) | 87 | $14,634 | $126 |
| Biopsy of large bowel using a flexible endoscope | 73 | $9,363 | $128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 90 | $8,202 | $85 |
| New patient visit (45+ min) | 54 | $7,486 | $139 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 35 | $7,480 | $214 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 34 | $6,707 | $197 |
| Short return visit (20+ min) | 91 | $6,318 | $63 |
| New patient visit (60+ min) | 27 | $4,854 | $180 |
| New patient visit (30+ min) | 33 | $3,172 | $96 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,482 | $207 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,416 | $151 |
| Short return visit | 19 | $786 | $41 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $315 | $21 |
2017: 10 services
| Biopsy of large bowel using a flexible endoscope | 71 | $10,830 | $153 |
| Return visit (30+ min) | 97 | $10,783 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 87 | $7,501 | $81 |
| Long return visit (40+ min) | 44 | $6,925 | $121 |
| Diagnostic exam of large bowel using a flexible endoscope | 36 | $5,442 | $151 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,679 | $213 |
| Destruction of polyp or growth of large bowel using a flexible endoscope | 13 | $2,903 | $223 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,778 | $198 |
| Short return visit (20+ min) | 31 | $1,991 | $60 |
| New patient visit (45+ min) | 11 | $1,300 | $118 |
2016: 9 services
| Biopsy of large bowel using a flexible endoscope | 74 | $10,719 | $145 |
| Return visit (30+ min) | 92 | $10,682 | $89 |
| Long return visit (40+ min) | 55 | $9,016 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 75 | $6,566 | $85 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $5,374 | $192 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $4,378 | $156 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $3,131 | $209 |
| Short return visit (20+ min) | 31 | $2,043 | $62 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,247 | $96 |
2015: 8 services
| Return visit (30+ min) | 117 | $14,124 | $92 |
| Biopsy of large bowel using a flexible endoscope | 70 | $12,271 | $173 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 46 | $11,356 | $247 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 76 | $7,186 | $91 |
| Long return visit (40+ min) | 42 | $6,501 | $130 |
| Diagnostic exam of large bowel using a flexible endoscope | 35 | $6,312 | $180 |
| Short return visit (20+ min) | 42 | $2,806 | $57 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,750 | $229 |
2014: 10 services
| Biopsy of large bowel using a flexible endoscope | 77 | $14,133 | $184 |
| Return visit (30+ min) | 104 | $12,500 | $91 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 97 | $9,696 | $95 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $9,496 | $250 |
| Diagnostic exam of large bowel using a flexible endoscope | 39 | $7,261 | $186 |
| Long return visit (40+ min) | 39 | $5,914 | $126 |
| Short return visit (20+ min) | 65 | $4,859 | $62 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,854 | $241 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 13 | $3,131 | $241 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,078 | $98 |
2013: 10 services
| Biopsy of large bowel using a flexible endoscope | 82 | $16,698 | $201 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 122 | $15,876 | $116 |
| Return visit (30+ min) | 97 | $12,665 | $95 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | $10,944 | $261 |
| Diagnostic exam of large bowel using a flexible endoscope | 47 | $8,259 | $176 |
| Long return visit (40+ min) | 33 | $5,556 | $129 |
| Short return visit (20+ min) | 50 | $3,276 | $60 |
| Removal of polyps or growths in large bowel using an endoscope | 11 | $3,231 | $294 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,860 | $238 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,874 | $125 |
Drugs they prescribed that Part D paid
$317,494
Pharmacies billed $317,494 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 408) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
356 generic and 52 brand-name prescriptions · $317,494 in drug cost · 23 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mesalamine | 27 | $9,350 | $346 |
| Famotidine | 113 | $1,471 | $13 |
| Omeprazole | 92 | $1,166 | $13 |
| Peg 3350-Electrolyte | 21 | $427 | $20 |
Year by year
| 2024 | 408 | 159 | 0% (0) | 13% | $317,494 |
| 2023 | 314 | 118 | 0% (0) | 11% | $219,469 |
| 2022 | 421 | 131 | 0% (0) | 18% | $263,729 |
| 2021 | 324 | 159 | 0% (0) | 35% | $211,669 |
| 2020 | 47 | 26 | 0% (0) | None | $5,338 |
| 2019 | 92 | 53 | None | 28% | $24,905 |
| 2018 | 382 | 142 | 0% (0) | 22% | $66,892 |
| 2017 | 880 | 257 | 0% (0) | 31% | $132,731 |
| 2016 | 887 | 212 | 0% (0) | None | $149,253 |
| 2015 | 1,053 | 213 | None | None | $388,644 |
| 2014 | 1,152 | 252 | None | 34% | $368,506 |
| 2013 | 948 | 252 | None | 42% | $162,304 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Linzess | 11 | $9,929 | $903 |
| Famotidine | 71 | $1,530 | $22 |
| Omeprazole | 91 | $1,448 | $16 |
2022: 6 drugs
| Mesalamine | 26 | $15,304 | $589 |
| Linzess | 16 | $12,177 | $761 |
| Suprep | 21 | $2,441 | $116 |
| Famotidine | 105 | $2,136 | $20 |
| Omeprazole | 97 | $1,360 | $14 |
| Escitalopram | 24 | $275 | $11 |
2021: 4 drugs
| Mesalamine | 16 | $7,860 | $491 |
| Suprep | 66 | $7,450 | $113 |
| Famotidine | 42 | $1,315 | $31 |
| Omeprazole | 61 | $1,073 | $18 |
2018: 8 drugs
| Amitiza | 13 | $5,641 | $434 |
| Omeprazole | 96 | $1,538 | $16 |
| Ranitidine | 46 | $1,152 | $25 |
| Pantoprazole | 21 | $551 | $26 |
| Loperamide | 11 | $393 | $36 |
| Peg 3350-Electrolyte | 20 | $358 | $18 |
| Gavilyte-N | 12 | $170 | $14 |
| Amitriptyline | 18 | $147 | $8 |
2017: 19 drugs
| Lialda | 22 | $23,099 | $1,050 |
| Canasa | 12 | $17,015 | $1,418 |
| Dexilant | 30 | $11,097 | $370 |
| Creon | 19 | $6,628 | $349 |
| Ursodiol | 15 | $5,001 | $333 |
| Amitiza | 12 | $4,154 | $346 |
| Nexium | 11 | $3,307 | $301 |
| Esomeprazole Magnesium | 22 | $2,772 | $126 |
| Ranitidine | 118 | $2,357 | $20 |
| Omeprazole | 161 | $2,273 | $14 |
| Peg 3350-Electrolyte | 105 | $1,581 | $15 |
| Suprep | 16 | $1,407 | $88 |
| Pantoprazole | 74 | $1,346 | $18 |
| Lansoprazole | 29 | $1,061 | $37 |
| Mirtazapine | 15 | $937 | $62 |
| Loperamide | 20 | $594 | $30 |
| Gavilyte-N | 27 | $479 | $18 |
| Polyethylene Glycol 3350 | 15 | $348 | $23 |
| Amitriptyline | 37 | $279 | $8 |
2016: 18 drugs
| Canasa | 15 | $29,918 | $1,995 |
| Lialda | 37 | $26,832 | $725 |
| Dexilant | 38 | $12,644 | $333 |
| Nexium | 28 | $9,176 | $328 |
| Creon | 11 | $5,276 | $480 |
| Esomeprazole Magnesium | 28 | $4,285 | $153 |
| Amitiza | 11 | $3,623 | $329 |
| Omeprazole | 195 | $2,804 | $14 |
| Ranitidine | 94 | $2,101 | $22 |
| Pantoprazole | 88 | $1,706 | $19 |
| Lansoprazole | 34 | $1,283 | $38 |
| Misoprostol | 15 | $934 | $62 |
| Peg 3350-Electrolyte | 54 | $825 | $15 |
| Mirtazapine | 18 | $655 | $36 |
| Loperamide | 20 | $519 | $26 |
| Polyethylene Glycol 3350 | 17 | $453 | $27 |
| Gavilyte-N | 15 | $253 | $17 |
| Amitriptyline | 31 | $219 | $7 |
2015: 21 drugs
| Lialda | 49 | $31,143 | $636 |
| Canasa | 14 | $21,748 | $1,553 |
| Dexilant | 64 | $17,796 | $278 |
| Nexium | 39 | $16,819 | $431 |
| Creon | 14 | $7,898 | $564 |
| Ursodiol | 11 | $7,810 | $710 |
| Carafate | 13 | $5,258 | $404 |
| Amitiza | 12 | $3,756 | $313 |
| Omeprazole | 235 | $3,414 | $15 |
| Rabeprazole | 20 | $2,995 | $150 |
| Pantoprazole | 133 | $2,319 | $17 |
| Lansoprazole | 38 | $1,783 | $47 |
| Ranitidine | 79 | $1,673 | $21 |
| Misoprostol | 18 | $1,410 | $78 |
| Ondansetron | 49 | $927 | $19 |
| Loperamide | 23 | $542 | $24 |
| Peg 3350-Electrolyte | 31 | $542 | $17 |
| Polyethylene Glycol 3350 | 11 | $328 | $30 |
| Gavilyte-N | 16 | $318 | $20 |
| Mirtazapine | 16 | $201 | $13 |
| Amitriptyline | 26 | $168 | $6 |
2014: 25 drugs
| Nexium | 71 | $29,602 | $417 |
| Lialda | 39 | $21,213 | $544 |
| Budesonide Ec | 11 | $14,931 | $1,357 |
| Rabeprazole | 44 | $14,585 | $331 |
| Dexilant | 59 | $13,544 | $230 |
| Linzess | 15 | $6,790 | $453 |
| Carafate | 14 | $4,382 | $313 |
| Amitiza | 12 | $3,615 | $301 |
| Pantoprazole | 165 | $3,428 | $21 |
| Omeprazole | 197 | $3,388 | $17 |
| Misoprostol | 20 | $1,917 | $96 |
| Moviprep | 24 | $1,864 | $78 |
| Ranitidine | 48 | $1,818 | $38 |
| Peg-3350 | 50 | $873 | $17 |
| Polyethylene Glycol 3350 | 16 | $660 | $41 |
| Ondansetron Odt | 13 | $621 | $48 |
| Lansoprazole | 12 | $607 | $51 |
| Loperamide | 21 | $492 | $23 |
| Gavilyte-N | 22 | $427 | $19 |
| Ondansetron | 28 | $426 | $15 |
| Sucralfate | 12 | $392 | $33 |
| Mirtazapine | 22 | $228 | $10 |
| Ciprofloxacin | 16 | $173 | $11 |
| Amitriptyline | 30 | $145 | $5 |
| Propranolol | 11 | $61 | $6 |
2013: 24 drugs
| Nexium | 69 | $22,735 | $329 |
| Xifaxan | 15 | $16,109 | $1,074 |
| Aciphex | 19 | $9,637 | $507 |
| Budesonide Ec | 13 | $7,420 | $571 |
| Lialda | 18 | $6,800 | $378 |
| Asacol | 11 | $5,827 | $530 |
| Dexilant | 26 | $5,571 | $214 |
| Suprep | 70 | $5,069 | $72 |
| Pantoprazole | 140 | $4,434 | $32 |
| Omeprazole | 137 | $3,275 | $24 |
| Ursodiol | 15 | $3,140 | $209 |
| Amitiza | 11 | $2,968 | $270 |
| Misoprostol | 28 | $2,256 | $81 |
| Escitalopram | 11 | $1,896 | $172 |
| Moviprep | 23 | $1,654 | $72 |
| Lansoprazole | 25 | $1,582 | $63 |
| Ranitidine | 49 | $1,533 | $31 |
| Polyethylene Glycol 3350 | 12 | $447 | $37 |
| Loperamide | 13 | $339 | $26 |
| Peg-3350 and Electrolytes | 20 | $333 | $17 |
| Peg-3350 With Flavor Packs | 11 | $206 | $19 |
| Mirtazapine | 14 | $164 | $12 |
| Ciprofloxacin | 14 | $128 | $9 |
| Amitriptyline | 16 | $52 | $3 |
Money from drug and device companies
$1,211 in 2025
| 2025 | 11 | 50 | None | $1,211 |
| 2022 | 3 | 3 | None | $68 |
| 2021 | 2 | 2 | None | $33 |
| 2020 | 1 | 1 | None | $18 |
| 2019 | 5 | 12 | None | $217 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Omvoh | $360 | 9 payments
|
| Janssen Biotech | Tremfya | $250 | 17 payments
|
| Abbvie | Rinvoq | $176 | 7 payments
|
| Celltrion USA | Vegzelma | $150 | 7 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $121 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $46 | 2 payments
|
See all 50 published payments
| Abbvie | Meals · 2025-12-11 | Skyrizi | $28 |
| Janssen Biotech | Meals · 2025-12-03 | Tremfya | $14 |
| Ipsen Biopharmaceuticals | Meals · 2025-11-20 | Iqirvo | $29 |
| Janssen Biotech | Meals · 2025-11-19 | Tremfya | $14 |
| Pfizer | Meals · 2025-11-18 | Velsipity | $18 |
| Exact Sciences | Meals · 2025-11-13 | None | $22 |
| Madrigal Pharmaceuticals | Meals · 2025-11-05 | Rezdiffra | $24 |
| Celltrion USA | Meals · 2025-11-04 | Vegzelma | $15 |
| Abbvie | Meals · 2025-10-17 | Rinvoq | $31 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-13 | Xifaxan | $23 |
| Janssen Biotech | Meals · 2025-09-29 | Tremfya | $15 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $15 |
| Celltrion USA | Meals · 2025-09-19 | Vegzelma | $22 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $13 |
| Lilly USA | Meals · 2025-09-08 | Omvoh | $122 |
| Janssen Biotech | Meals · 2025-09-03 | Tremfya | $2 |
| Janssen Biotech | Meals · 2025-09-03 | Tremfya | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-25 | Xifaxan | $23 |
| Janssen Biotech | Meals · 2025-08-13 | Tremfya | $11 |
| Celltrion USA | Meals · 2025-08-13 | Vegzelma | $12 |
| Lilly USA | Meals · 2025-08-11 | Omvoh | $30 |
| Abbvie | Meals · 2025-08-08 | Rinvoq | $29 |
| Braintree Laboratories | Meals · 2025-08-06 | Suflave | $23 |
| Lilly USA | Meals · 2025-07-22 | Omvoh | $35 |
| Lilly USA | Meals · 2025-07-22 | Omvoh | $34 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $12 |
| Madrigal Pharmaceuticals | Meals · 2025-07-09 | Rezdiffra | $47 |
| Celltrion USA | Meals · 2025-07-09 | Vegzelma | $17 |
| Janssen Biotech | Meals · 2025-06-24 | Tremfya | $14 |
| Lilly USA | Meals · 2025-06-18 | Omvoh | $32 |
| Janssen Biotech | Meals · 2025-06-17 | Tremfya | $16 |
| Intercept Pharmaceuticals | Meals · 2025-06-12 | Ocaliva | $17 |
| Janssen Biotech | Meals · 2025-05-27 | Tremfya | $15 |
| Abbvie | Meals · 2025-05-23 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-05-20 | Tremfya | $12 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $13 |
| Lilly USA | Meals · 2025-05-08 | Omvoh | $33 |
| Celltrion USA | Meals · 2025-05-07 | Vegzelma | $28 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $10 |
| Abbvie | Meals · 2025-04-16 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-04-10 | Tremfya | $13 |
| Abbvie | Meals · 2025-04-09 | Rinvoq | $19 |
| Celltrion USA | Meals · 2025-04-08 | Vegzelma | $17 |
| Lilly USA | Meals · 2025-04-02 | Omvoh | $35 |
| Madrigal Pharmaceuticals | Meals · 2025-04-01 | Rezdiffra | $50 |
| Lilly USA | Meals · 2025-03-11 | Omvoh | $22 |
| Janssen Biotech | Meals · 2025-03-06 | Tremfya | $39 |
| Celltrion USA | Meals · 2025-03-05 | Vegzelma | $39 |
| Lilly USA | Meals · 2025-01-08 | Omvoh | $19 |
See earlier years (2022, 2021, 2020, 2019)
2022: $68
| Abbvie | Linzess | $31 | 1 payment
|
| PENTAX of America | C2 Cryoballoon | $22 | 1 payment
|
| Janssen Biotech | Stelara | $15 | 1 payment
|
2021: $33
| AbbVie | Linzess | $18 | 1 payment
|
| Janssen Biotech | Stelara | $15 | 1 payment
|
2020: $18
| W. L. Gore & Associates | Cardioform Septal Occluder | $18 | 1 payment
|
2019: $217
| Takeda Pharmaceuticals U.S.A. | Entyvio | $64 | 3 payments
|
| Pfizer | Xeljanz | $59 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $44 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $34 | 2 payments
|
| Janssen Biotech | Stelara | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396717740
- Licence
- CA A50154California A50154: Current · expires 2027-05-31
- Group
- Stanford Health Care · El Camino Health Medical Network LLC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-02-01
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2490 Hospital Dr, Mountain View, CA, 94040